Eli Lilly and Co
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder
- Conditions
- First Posted Date
- 2002-11-27
- Last Posted Date
- 2007-06-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 130
- Registration Number
- NCT00050206
- Locations
- ๐บ๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Indianapolis, Indiana, United States
A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)
- Conditions
- First Posted Date
- 2002-11-15
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2000
- Registration Number
- NCT00049777
- Locations
- ๐ฉ๐ช
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician, Berlin, Germany
Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis
- First Posted Date
- 2002-11-14
- Last Posted Date
- 2007-11-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 474
- Registration Number
- NCT00049764
- Locations
- ๐ฌ๐ง
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Southhampton, United Kingdom
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
- Conditions
- First Posted Date
- 2002-09-23
- Last Posted Date
- 2006-07-20
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00046137
- Locations
- ๐บ๐ธ
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician"., Dallas, Texas, United States
The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis
- Conditions
- First Posted Date
- 2002-09-10
- Last Posted Date
- 2006-07-20
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00045760
- Locations
- ๐บ๐ธ
timoreFor additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Baltimore, Maryland, United States
๐ฌ๐งFor additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Northampton, United Kingdom
๐ซ๐ฎFor additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Turku, Finland
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2002-09-09
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT00044863
- Locations
- ๐บ๐ธ
ImClone Investigational Site, St. Charles, Missouri, United States
Treatment of Peripheral Neuropathy in Patients With Diabetes
- Conditions
- First Posted Date
- 2002-08-30
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 400
- Registration Number
- NCT00044421
- Locations
- ๐ฌ๐ง
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
๐ช๐ธFor additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Dos Hermanas, Sevilla, Spain
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
- Conditions
- First Posted Date
- 2002-08-30
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT00044395
- Locations
- ๐ช๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Madrid, Spain
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
- Conditions
- First Posted Date
- 2002-08-23
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 130
- Registration Number
- NCT00044187
A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
- First Posted Date
- 2002-08-06
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 55
- Registration Number
- NCT00042666
- Locations
- ๐บ๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, Minnesota, United States